Monday, October 18, 2021 Daily Archives

TESSA Technology: A Plasmid-Free, Scalable System to Transform AAV Manufacture

by

This webcast features: Dr. Weiheng Su, Principal Scientist, OXGENE Adenoassociated virus (AAV) is a popular choice of viral vector for new gene therapies, but manufacturing systems have not kept pace with biological advances, leaving these therapies costly, difficult to produce at scale, and subject to inherent batch-to-batch variability. In this webinar, Dr. Weiheng Su describes how rethinking AAV manufacture “from the ground up†allowed OXGENE to manipulate AAV’s natural relationship with adenovirus to address these challenges with their novel tetracycline-enabled…

October 18, 2021

Standardized cleanrooms give biopharma the speed it needs

by

When we began building our cleanroom PODs a little over ten years ago, more than one industry stalwart expressed confusion and/or concern as to how our prefabricated approach would even work. I came up with several quick retorts like “When you buy a bioreactor, do you design it yourself and have it assembled at your site?†Some would get it. Some took more convincing. We decided to convince further by consistently getting better. When we grew to adolescence and had…

October 18, 2021

Cellectis unveils NC plant, adding in-house capabilities

by

Cellectis has opened its clinical and commercial manufacturing facility in Raleigh, North Carolina making it a one-stop-shop company, says firm. France-headquartered Cellectis announced plans in March 2019 to construct a clinical and commercial production plant in Raleigh, North Carolina at a reported cost of $68 million to support its allogeneic universal chimeric antigen receptor t-cells (UCART) products. The 82,000 square-foot facility has been operational for a couple of months but Cellectis did an official opening earlier this month. The gene editing…

October 18, 2021

Fujifilm breaks ground on 160,000 L mammalian plant in NC

by

Fujifilm Diosynth’s CEO Martin Meeson sees no slowdown in demand for CDMO capacity across all modalities as work begins on a $1.8 billion mammalian cell culture plant in North Carolina. In March, contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies selected Holly Springs, North Carolina as the site of its latest addition to its biomanufacturing network. Construction began last week on the Â¥200 billion ($1.8 billion), and once operational in 2025 it will offer biopharma customers 8 x 20,000…

October 18, 2021